02:55 PM EDT, 05/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $158 from $193, 12.3x our 2026 EPS of $12.88 (down from $13.20), below IQV's five-year historical forward P/E average of 21.6x. We lift our 2025 view to $12.02 from $11.95 to reflect today's beat. IQVIA ( IQV ) reported Q1 revenue of $3.8B (+2.5% Y/Y), driven by the strong performance of the Technology & Analytics segment sales, which grew 7.6% Y/Y at constant currency. Yet, the R&D segment, which accounts for the majority of IQVIA's ( IQV ) revenue, showed only modest sales growth of 0.3% Y/Y (1.1% at constant currency). In our view, this tepid performance reflects ongoing challenges in the biopharmaceutical industry, including delayed decision making on new programs and increased caution in spending among large pharma clients. We believe IQVIA's ( IQV ) diversified business model and solid position in health care analytics could provide resilience against industry headwinds, though the maintained profit guidance suggests potential margin pressure ahead.